---
title: "Weekly Recap | ABSI.US +13.66%, most brokers rate it buy"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/300845990.md"
description: "Absci (ABSI) finished the week up 13.66% at $11.07, outpacing the S&P 500 by roughly 13.93 percentage points. The move was front-loaded: Monday dipped to $9.25 before the stock recovered through Tuesday’s break above $10, pushed to $10.99 on Wednesday, then consolidated around $11 after touching $11.27 on Thursday. Weekly amplitude came in at 21.89%, and average daily volume ran about 36.8% above the 60-day median, a sign that participation widened alongside the rally."
datetime: "2026-10-03T06:09:16.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/300845990.md)
  - [en](https://longbridge.com/en/news/300845990.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/300845990.md)
generator: "portal-rs"
---

# Weekly Recap | ABSI.US +13.66%, most brokers rate it buy

## The Week

Absci (ABSI) finished the week up 13.66% at $11.07, outpacing the S&P 500 by roughly 13.93 percentage points. The move was front-loaded: Monday dipped to $9.25 before the stock recovered through Tuesday’s break above $10, pushed to $10.99 on Wednesday, then consolidated around $11 after touching $11.27 on Thursday. Weekly amplitude came in at 21.89%, and average daily volume ran about 36.8% above the 60-day median, a sign that participation widened alongside the rally.

## Key Events

Company-specific headlines were thin this week; the story was more about the AI theme rippling across small caps. On Tuesday, Rumble announced a $13.7B compute deal with Anthropic, reviving the microcap pivot-to-AI narrative and lifting sentiment across adjacent AI-biotech names. The following morning, a report directly flagging Absci appeared, and the stock jumped 6.1% on Wednesday. The rally looks more like a risk-appetite rotation into small-cap AI plays than a response to any standalone company catalyst.

## Analyst Ratings

Of the 11 brokers covering the stock, 8 rate it buy, 2 rate it overweight, and 1 rates it hold, with no sell or underweight ratings. The consensus recommendation is strong buy. The consensus target sits at $14.40, about 30.1% above the last close. Targets range from $10 to $17, a wide spread in which the low end is already below spot while the high end implies roughly 53% upside. Within the biotech industry’s 507 names, Absci ranks 128th by rating, placing it in the upper-middle tier but not among the top group.

## The Week Ahead

The macro calendar is heavy: S&P Global services PMI and ISM non-manufacturing PMI on Monday, international trade data on Tuesday, and EIA crude inventories on Wednesday. For a mid-cap growth name, services and trade prints will mainly feed into overall risk appetite. The more direct question is whether the AI-biotech momentum can hold into next week without fresh company-specific news, or whether the rally needs new filings or clinical updates to avoid drifting.

## In Short

The tension this week sits between a bullish-leaning broker profile—with consensus target well above spot—and the unusually wide target range, which suggests the market has not settled on a stable valuation anchor. The stock’s strength against a falling S&P 500 reads more as a concentrated recovery in small-cap growth and AI thematics than as a company-specific fundamental move. What follows is whether this thematic repair can flatten into a steadier trend without dedicated catalysts, or whether macro shifts and risk-appetite swings trigger a quick give-back.

*This article is generated by LongbridgeAI from market data, for information only and not investment advice.*

### Related Stocks

- [ABSI.US](https://longbridge.com/en/quote/ABSI.US.md)

## Related News & Research

- [Absci Stock In Focus As Phase 2 Trial Plan Takes Shape](https://longbridge.com/en/news/300210350.md)
- [Absci (ABSI) Maps Out Phase 2 Trial, Is It Still 29% Undervalued?](https://longbridge.com/en/news/300064442.md)
- [Tesla's Q3 Delivery Beat Is Just the Start: Gene Munster Says TSLA Will ‘Crush Traditional Automakers’](https://longbridge.com/en/news/300968018.md)
- [Is Oracle Stock a Good Buy While It's Trading Below $150?](https://longbridge.com/en/news/300960808.md)
- [‘One for the Kids,’ Says Top Investor About SpaceX Stock](https://longbridge.com/en/news/300955937.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**